241 related articles for article (PubMed ID: 23159171)
1. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.
Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Zalutsky MR
Nucl Med Biol; 2013 Jan; 40(1):52-9. PubMed ID: 23159171
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.
Vaidyanathan G; Jestin E; Olafsen T; Wu AM; Zalutsky MR
Nucl Med Biol; 2009 Aug; 36(6):671-80. PubMed ID: 19647173
[TBL] [Abstract][Full Text] [Related]
3. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.
Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Lyerly HK; Zalutsky MR
J Nucl Med; 2014 Apr; 55(4):650-6. PubMed ID: 24578241
[TBL] [Abstract][Full Text] [Related]
4. D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination.
Pruszynski M; Koumarianou E; Vaidyanathan G; Chitneni S; Zalutsky MR
Nucl Med Biol; 2015 Jan; 42(1):19-27. PubMed ID: 25240914
[TBL] [Abstract][Full Text] [Related]
5. d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution.
Pruszynski M; Kang CM; Koumarianou E; Vaidyanathan G; Zalutsky MR
Molecules; 2018 May; 23(5):. PubMed ID: 29783774
[TBL] [Abstract][Full Text] [Related]
6. Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.
Feng Y; Zhou Z; McDougald D; Meshaw RL; Vaidyanathan G; Zalutsky MR
Nucl Med Biol; 2021 Jan; 92():171-183. PubMed ID: 32448731
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.
Vaidyanathan G; McDougald D; Choi J; Koumarianou E; Weitzel D; Osada T; Lyerly HK; Zalutsky MR
J Nucl Med; 2016 Jun; 57(6):967-73. PubMed ID: 26912425
[TBL] [Abstract][Full Text] [Related]
8. Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.
Zhou Z; Chitneni SK; Devoogdt N; Zalutsky MR; Vaidyanathan G
Bioorg Med Chem; 2018 May; 26(8):1939-1949. PubMed ID: 29534937
[TBL] [Abstract][Full Text] [Related]
9. Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies.
Vaidyanathan G; Alston KL; Bigner DD; Zalutsky MR
Bioconjug Chem; 2006; 17(4):1085-92. PubMed ID: 16848419
[TBL] [Abstract][Full Text] [Related]
10. Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.
Choi J; Vaidyanathan G; Koumarianou E; Kang CM; Zalutsky MR
Nucl Med Biol; 2018 Jan; 56():10-20. PubMed ID: 29031230
[TBL] [Abstract][Full Text] [Related]
11. Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.
Zhou Z; Vaidyanathan G; McDougald D; Kang CM; Balyasnikova I; Devoogdt N; Ta AN; McNaughton BR; Zalutsky MR
Mol Imaging Biol; 2017 Dec; 19(6):867-877. PubMed ID: 28409338
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an Anti-HER2 Nanobody Labeled with
Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
[TBL] [Abstract][Full Text] [Related]
13. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
[TBL] [Abstract][Full Text] [Related]
14. Site-Specific and Residualizing Linker for
Zhou Z; Meshaw R; Zalutsky MR; Vaidyanathan G
J Nucl Med; 2021 Nov; 62(11):1624-1630. PubMed ID: 33637584
[TBL] [Abstract][Full Text] [Related]
15. N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization.
Choi J; Vaidyanathan G; Koumarianou E; McDougald D; Pruszynski M; Osada T; Lahoutte T; Lyerly HK; Zalutsky MR
Nucl Med Biol; 2014; 41(10):802-12. PubMed ID: 25156548
[TBL] [Abstract][Full Text] [Related]
16. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
[TBL] [Abstract][Full Text] [Related]
17. (18)F-nanobody for PET imaging of HER2 overexpressing tumors.
Xavier C; Blykers A; Vaneycken I; D'Huyvetter M; Heemskerk J; Lahoutte T; Devoogdt N; Caveliers V
Nucl Med Biol; 2016 Apr; 43(4):247-52. PubMed ID: 27067045
[TBL] [Abstract][Full Text] [Related]
18. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A
Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850
[TBL] [Abstract][Full Text] [Related]
19. Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[
Zhou Z; McDougald D; Devoogdt N; Zalutsky MR; Vaidyanathan G
Mol Pharm; 2019 Jan; 16(1):214-226. PubMed ID: 30427188
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]